Evaluation of urate-lowering efficacy of isolated and combined use of febuxostat and empagliflozin in patients with gout and type 2 diabetes mellitus (OPORA Clinical Trial)
Abstract
Introduction. Given the increasing frequency of the association of gout and type 2 diabetes, it is necessary to study the impact of modern therapy on their course.Aim. To evaluate the influence of isolated and combined use of febuxostat and empagliflozin on metabolic parameters and inflammatory markers in patients with gout and type 2 diabetes.Materials and methods. The “OPORA” study included 120 men aged 40–65 years with the simultaneous presence of gout and type 2 diabetes. The subjects were randomized into 3 groups (n = 40): group 1 (F), receiving febuxostat 80 mg/day; group 2 (E) – empagliflozin 25 mg/day; group 3 (FE) – combination of drugs febuxostat 80 mg/day + empagliflozin 25 mg/day. The studied parameters were analyzed before the appointment of therapy and after 12 weeks of treatment.Results. The decrease in uric acid levels was most significant in group 1 (F) (Δ = 22.3%, p < 0.01). The most pronounced decrease in glucose levels was achieved in group 2 (E) (Δ = 32.2%, p < 0.01) and group 3 (FE) (Δ = 21.6%, p < 0.01). In group 3 (FE) a more significant decrease in insulin levels was revealed (Δ = 26.2%, p < 0.01) and HOMA-IR (Δ = 23.0%, p < 0.01) after 3 months. The most significant increase in the level of adiponectin and decrease in the level of leptin was noted in group 3 (FE), p < 0.01. The greatest effect in reducing indicators characterizing inflammation was observed in group 3 (PE) in the form of a significant decrease in the levels of ESR, CRP, TNF-a. After…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 120 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.